ROCKVILLE, Md., May 20, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the “Company”), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced that I-Mab’s management team will participate in the Jefferies Global Healthcare Conference, being held June 3-5, 2025. During the event, I-Mab’s management will discuss clinical progress on its lead program, givastomig.
I-Mab also recently announced that new data on givastomig has been accepted for a Mini Oral presentation at the European Society of Medical Oncology (“ESMO”) Gastrointestinal (“GI”) Cancers Congress 2025, scheduled for July 2, 2025, in Barcelona, Spain.
Conference details are as follows:
Jefferies Global Healthcare Conference
Format: Fireside Chat and one-on-one meetings
Date: Thursday, June 5, 2025
Time: 3:45 PM ET
Webcast Link: Register here
About I-Mab
I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. I-Mab has established operations in the U.S. in Rockville, Maryland, and Short Hills, New Jersey. For more information, please visit https://www.i-mabbiopharma.com and follow us on LinkedIn and X.
I-Mab Investor & Media Contacts
PJ Kelleher
LifeSci Advisors
+1-617-430-7579
pkelleher@lifesciadvisors.com
IR@imabbio.com

| Oct-22 | |
| Oct-16 | |
| Oct-15 | |
| Oct-14 | |
| Oct-10 | |
| Oct-07 | |
| Oct-06 | |
| Sep-23 | |
| Sep-08 | |
| Aug-28 | |
| Aug-25 | |
| Aug-21 |
I-Mab to Participate in September Investor Conferences
GlobeNewswire
|
| Aug-20 | |
| Aug-11 | |
| Aug-01 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, alerts, and much more.
Learn more about Finviz Elite